A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine
{"title":"先前接受parp抑制剂治疗的卵巢癌患者的维持性奥拉帕尼再挑战:患者报告的IIIB期OReO/engot-ov38试验结果","authors":"A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine","doi":"10.1136/ijgc-2022-igcs.27","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":312680,"journal":{"name":"Focused Plenary Abstracts","volume":"21 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial\",\"authors\":\"A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine\",\"doi\":\"10.1136/ijgc-2022-igcs.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":312680,\"journal\":{\"name\":\"Focused Plenary Abstracts\",\"volume\":\"21 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Focused Plenary Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-igcs.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focused Plenary Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-igcs.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial